Several meta-analyses proved that NSCLC patients with 19 Del had higher response rates and longer progression-free survival (PFS), overall survival (OS) after EGFR-TKI therapy compared with L858R. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.